NasdaqGM:FLGT

Stock Analysis Report

Executive Summary

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.

Risks

  • Fulgent Genetics has significant price volatility in the past 3 months.
  • Fulgent Genetics is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Fulgent Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.6%

FLGT

-1.2%

US Healthcare

-0.02%

US Market


1 Year Return

235.9%

FLGT

-9.4%

US Healthcare

1.6%

US Market

FLGT outperformed the Healthcare industry which returned -9.4% over the past year.

FLGT outperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

FLGTIndustryMarket
7 Day-1.6%-1.2%-0.02%
30 Day-7.8%-2.2%2.7%
90 Day97.3%-1.5%1.4%
1 Year235.9%235.9%-8.0%-9.4%3.8%1.6%
3 Yearn/a28.7%23.5%45.2%35.8%
5 Yearn/a62.7%53.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

Investors Who Bought Fulgent Genetics (NASDAQ:FLGT) Shares A Year Ago Are Now Up 38%

Valuation

Is Fulgent Genetics undervalued based on future cash flows and its price relative to the stock market?

34%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Fulgent Genetics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Fulgent Genetics's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Fulgent Genetics is loss making, we can't compare its value to the US Healthcare industry average.

Fulgent Genetics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Fulgent Genetics, we can't assess if its growth is good value.


Price Based on Value of Assets

Fulgent Genetics is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Fulgent Genetics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

153.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Fulgent Genetics's revenue is expected to grow significantly at over 20% yearly.

Fulgent Genetics's earnings are expected to grow significantly at over 20% yearly.

Fulgent Genetics's revenue growth is expected to exceed the United States of America market average.

Fulgent Genetics's earnings growth is expected to exceed the United States of America market average.

Fulgent Genetics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Fulgent Genetics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Fulgent Genetics performed over the past 5 years?

13.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Fulgent Genetics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Fulgent Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Fulgent Genetics's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Fulgent Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Fulgent Genetics has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Fulgent Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Fulgent Genetics's financial position?


Financial Position Analysis

Fulgent Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Fulgent Genetics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Fulgent Genetics's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Fulgent Genetics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 7.8351374517179E+16x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Fulgent Genetics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Fulgent Genetics has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 44.2% per year.


Next Steps

Dividend

What is Fulgent Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Fulgent Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Fulgent Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Fulgent Genetics has not reported any payouts.

Unable to verify if Fulgent Genetics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Fulgent Genetics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Fulgent Genetics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Fulgent Genetics's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Ming Hsieh (63yo)

3.3yrs

Tenure

US$240,000

Compensation

Mr. Ming Hsieh is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and served as its Manager. Mr. Hsieh serves as President at Fulgent Therapeutics, ...


CEO Compensation Analysis

Ming's remuneration is lower than average for companies of similar size in United States of America.

Ming's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.3yrs

Average Tenure

52yo

Average Age

The tenure for the Fulgent Genetics management team is about average.


Board Age and Tenure

3.0yrs

Average Tenure

65yo

Average Age

The tenure for the Fulgent Genetics board of directors is about average.


Insider Trading

Fulgent Genetics individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$142,44814 Aug 19
Paul Kim
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares12,389
Max PriceUS$11.52
SellUS$7,72214 May 19
Paul Kim
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,404
Max PriceUS$5.50
BuyUS$43,24008 Mar 19
Ming Hsieh
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares8,739
Max PriceUS$4.95
SellUS$5,44106 Mar 19
Paul Kim
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,165
Max PriceUS$4.67
BuyUS$39,03215 Nov 18
Ming Hsieh
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares10,880
Max PriceUS$3.59
SellUS$5,06214 Nov 18
Paul Kim
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,446
Max PriceUS$3.50
BuyUS$33,61013 Nov 18
Ming Hsieh
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares10,000
Max PriceUS$3.36

Ownership Breakdown


Management Team

  • Paul Kim (52yo)

    Chief Financial Officer

    • Tenure: 3.7yrs
    • Compensation: US$241.12k
  • Ming Hsieh (63yo)

    Chairman

    • Tenure: 3.3yrs
    • Compensation: US$240.00k
  • Harry Gao (52yo)

    Chief Scientific Officer & Laboratory Director

    • Tenure: 3yrs
    • Compensation: US$216.30k

Board Members

  • John Bolger (72yo)

    Independent Director

    • Tenure: 3yrs
    • Compensation: US$72.60k
  • Ming Hsieh (63yo)

    Chairman

    • Tenure: 3.3yrs
    • Compensation: US$240.00k
  • Yun Yen (64yo)

    Independent Director

    • Tenure: 3yrs
    • Compensation: US$53.50k
  • Mulé Mulay (66yo)

    Independent Director

    • Tenure: 3yrs
    • Compensation: US$70.10k
  • Linda Marsh

    Director

    • Tenure: 0.08yrs

Company Information

Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fulgent Genetics, Inc.
  • Ticker: FLGT
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$204.272m
  • Shares outstanding: 18.49m
  • Website: https://www.fulgentgenetics.com

Number of Employees


Location

  • Fulgent Genetics, Inc.
  • 4978 Santa Anita Avenue
  • Suite 205
  • Temple City
  • California
  • 91780
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FLGTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2016

Biography

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 01:29
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.